{
    "2019-08-14": [
        [
            {
                "time": "",
                "original_text": "长春高新上半年疫苗板块下滑明显，净利润同比下降30.8% 盈利能力下降",
                "features": {
                    "keywords": [
                        "长春高新",
                        "疫苗",
                        "板块下滑",
                        "净利润下降",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "长春高新: 生长激素业务持续快速增长, 疫苗下半年有望重回正轨",
                "features": {
                    "keywords": [
                        "长春高新",
                        "生长激素",
                        "业务增长",
                        "疫苗",
                        "下半年正轨"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "生长激素",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}